180 related articles for article (PubMed ID: 24857091)
1. The role of preclinical models in radiopharmaceutical therapy.
Sgouros G; Hobbs RF; Abou DS
Am Soc Clin Oncol Educ Book; 2014; ():e121-5. PubMed ID: 24857091
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry for radiopharmaceutical therapy.
Sgouros G; Hobbs RF
Semin Nucl Med; 2014 May; 44(3):172-8. PubMed ID: 24832581
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceutical therapy in the era of precision medicine.
Sgouros G; Goldenberg DM
Eur J Cancer; 2014 Sep; 50(13):2360-3. PubMed ID: 24953565
[TBL] [Abstract][Full Text] [Related]
4. A persistent belief in radiopharmaceutical therapy.
Sgouros G
Med Phys; 2023 Jun; 50 Suppl 1():104-108. PubMed ID: 36774195
[TBL] [Abstract][Full Text] [Related]
5. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
6. The Case for Dosimetry in Alpha-Emitter Therapy.
Sgouros G
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S45-S46. PubMed ID: 31537496
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
8. Current Status of Radiopharmaceutical Therapy.
St James S; Bednarz B; Benedict S; Buchsbaum JC; Dewaraja Y; Frey E; Hobbs R; Grudzinski J; Roncali E; Sgouros G; Capala J; Xiao Y
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):891-901. PubMed ID: 32805300
[TBL] [Abstract][Full Text] [Related]
9. Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
Sgouros G; Dewaraja YK; Escorcia F; Graves SA; Hope TA; Iravani A; Pandit-Taskar N; Saboury B; James SS; Zanzonico PB
J Nucl Med; 2021 Dec; 62(Suppl 3):12S-22S. PubMed ID: 34857617
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.
Divgi C; Carrasquillo JA; Meredith R; Seo Y; Frey EC; Bolch WE; Zimmerman BE; Akabani G; Jacobson DA; Brown B; Davern SM; Hobbs RF; Humm J; Moros EG; Morse D; Papineni R; Zanzonico P; Benedict SH; Sgouros G
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):905-912. PubMed ID: 33309909
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceutical therapy in cancer: clinical advances and challenges.
Sgouros G; Bodei L; McDevitt MR; Nedrow JR
Nat Rev Drug Discov; 2020 Sep; 19(9):589-608. PubMed ID: 32728208
[TBL] [Abstract][Full Text] [Related]
12. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
13. Theranostics and Patient-Specific Dosimetry.
Bednarz B
Semin Radiat Oncol; 2023 Jul; 33(3):317-326. PubMed ID: 37331786
[TBL] [Abstract][Full Text] [Related]
14. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
15. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
16. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney.
Bouchet LG; Bolch WE; Blanco HP; Wessels BW; Siegel JA; Rajon DA; Clairand I; Sgouros G
J Nucl Med; 2003 Jul; 44(7):1113-47. PubMed ID: 12843230
[TBL] [Abstract][Full Text] [Related]
17. Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls.
Ivashchenko OV; O'Doherty J; Hardiansyah D; Cremonesi M; Tran-Gia J; Hippeläinen E; Stokke C; Grassi E; Sandström M; Glatting G
Phys Med; 2024 Jan; 117():103192. PubMed ID: 38052710
[TBL] [Abstract][Full Text] [Related]
18. Role of lipid-soluble complexes in targeted tumor therapy.
Thakur ML; Coss R; Howell R; Vassileva-Belnikolovska D; Liu J; Rao SP; Spana G; Wachsberger P; Leeper DL
J Nucl Med; 2003 Aug; 44(8):1293-300. PubMed ID: 12902421
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the biodistribution of radiolabeled therapeutics in mice.
Fung EK; Zanzonico PB
Methods Cell Biol; 2023; 180():93-111. PubMed ID: 37890935
[TBL] [Abstract][Full Text] [Related]
20. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy.
Ting G; Chang CH; Wang HE
Anticancer Res; 2009 Oct; 29(10):4107-18. PubMed ID: 19846958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
